ADVM replaces CEO, delays clinical trial: http://endpts.com/post-merger-gene-therapy-player-adverum-names-amber-salzman-ceo-delays-a-clinical-trial-start/ The new CEO had been CEO of Annapurna Therapeutics, the company AAVL acquired in May 2016 in what was effectively a reverse merger (#msg-122582472).